REGN · News · 20260804N

Securities Fraud Litigation

REGENERON PHARMACEUTICALS, INC. · 2026-08-04 · Importance 34 · Surprise 42 · In source text

Multiple law firms reported that securities class actions have been filed against Regeneron and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The allegations concern investor-facing statements about the Phase 3 Fianlimab-Libtayo trial in advanced melanoma, including allegedly flawed statistical assumptions and inadequate disclosure of the trial’s likelihood of meeting its primary endpoint. The reported trial failure caused an approximately 9% share-price decline and an estimated $11 billion market-capitalization loss; investors from the August 1, 2025–May 15, 2026 class period have until September 14, 2026, to seek lead-plaintiff status.

Key facts

• A securities class action lawsuit has been filed on behalf of Regeneron investors after its stock plummeted almost 10% because Regeneron allegedly misled investors regarding the success of its Phase III Fianlimab-Libtayo clinical trial. source
• Hagens Berman and other filings state the failed Phase 3 melanoma trial news drove the price of Regeneron shares sharply lower and caused an $11 billion market cap wipeout. source
• Multiple law firms set a lead plaintiff deadline of September 14, 2026 for investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 to seek appointment in the securities class action. source
• News items repeatedly state the securities class action alleges Regeneron made false or misleading statements regarding its Phase III Fianlimab-Libtayo Study between August 1, 2025 and May 15, 2026, in alleged violation of §§10(b) and 20(a) and Rule 10b-5. source

Impact estimates